Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by icecubeon Jun 22, 2015 6:20pm

61 Views

Post# 23857160

RE:RE:Look at all the promoting going on here...

truthseeker2012 wrote: Desparate styless I don't think you will be getting any CPH at $9.00 as you wished for . I don't think every single Canadian biotech is up as you say "Every canadian pharma company is up at least 60-100% year to date". caught lying again so easy.

That may be true but $10 (which I believe was his original call), or even $9, is a lot closer than $15.

Bullboard Posts

Cameco raises uranium output as Q3 results surge